نتائج البحث - Yen‐Yang Chen

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    Outcomes of Liposomal Irinotecan With 5‐FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status

    Outcomes of Liposomal Irinotecan With 5‐FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status حسب Chieh-Ying Chang, Tai-Jan Chiu, Yen‐Yang Chen, Jen-Shi Chen, Wen-Chi Chou

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

    Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast canc... حسب Kun-Ming Rau, Yung‐Chang Lin, Yen-Yang Chen, Jen‐Shi Chen, Kuan‐Der Lee, Cheng‐Hsu Wang, Hsien-Kun Chang

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

    A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 حسب Chun‐Nan Yeh, Ming‐Huang Chen, Yen‐Yang Chen, Ching‐Yao Yang, Chueh‐Chuan Yen, Chin‐Yuan Tzen, Li‐Tzong Chen, Jen‐Shi Chen

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

    The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab حسب Jing‐Houng Wang, Yen‐Yang Chen, Kwong‐Ming Kee, Chih‐Chi Wang, Ming‐Chao Tsai, Yuan‐Hung Kuo, Chao‐Hung Hung, Weifeng Li, Hsiang‐Lan Lai, Yen‐Hao Chen

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients... حسب Hyun Cheol Chung, Yoon‐Koo Kang, Zhendong Chen, Yuxian Bai, Wan Zamaniah Wan Ishak, Byoung Yong Shim, Young Lee Park, Dong‐Hoe Koo, Jianwei Lu, Jianming Xu, Hong Jae Chon, Li‐Yuan Bai, Shan Zeng, Ying Yuan, Yen‐Yang Chen, Kangsheng Gu, Wen Yan Zhong, Shu Kuang, Chie‐Schin Shih, Shukui Qin

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: